BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cao D, Song Q, Li J, Jiang Y, Wang Z, Lu S. Opportunities and challenges in targeted therapy and immunotherapy for pancreatic cancer. Expert Rev Mol Med 2021;23:e21. [PMID: 34906271 DOI: 10.1017/erm.2021.26] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Gianfredi V, Nucci D, Nardi M, Santangelo OE, Provenzano S. Using Google Trends and Wikipedia to Investigate the Global Public’s Interest in the Pancreatic Cancer Diagnosis of a Celebrity. IJERPH 2023;20:2106. [DOI: 10.3390/ijerph20032106] [Reference Citation Analysis]
2 He X, Wang N, Zhang Y, Huang X, Wang Y. The therapeutic potential of natural products for treating pancreatic cancer. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1051952] [Reference Citation Analysis]
3 Jiang W, Li X, Xiang C, Zhou W. Neutrophils in pancreatic cancer: Potential therapeutic targets. Front Oncol 2022;12:1025805. [DOI: 10.3389/fonc.2022.1025805] [Reference Citation Analysis]
4 Su Y, Qi R, Li L, Wang X, Li S, Zhao X, Hou R, Ma W, Liu D, Zheng J, Shi M. An immune-related gene prognostic risk index for pancreatic adenocarcinoma. Front Immunol 2022;13:945878. [DOI: 10.3389/fimmu.2022.945878] [Reference Citation Analysis]
5 Xu J, Xu J, Liu X, Jiang J. The role of lncRNA-mediated ceRNA regulatory networks in pancreatic cancer. Cell Death Discov 2022;8:287. [PMID: 35697671 DOI: 10.1038/s41420-022-01061-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
6 Tian S, Guo Y, Fu J, Li Z, Li J, Tian X, Hussein AF. Prognostic Value of Immunotyping Combined with Targeted Therapy in Patients with Non-Small-Cell Lung Cancer and Establishment of Nomogram Model. Computational and Mathematical Methods in Medicine 2022;2022:1-9. [DOI: 10.1155/2022/3049619] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Chapa-gonzález C, López K, Lomelí KM, Roacho-pérez JA, Stevens JC. A Review on the Efficacy and Safety of Nab-Paclitaxel with Gemcitabine in Combination with Other Therapeutic Agents as New Treatment Strategies in Pancreatic Cancer. Life 2022;12:327. [DOI: 10.3390/life12030327] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Bolm L, Zemskov S, Zeller M, Baba T, Roldan J, Harrison JM, Petruch N, Sato H, Petrova E, Lapshyn H, Braun R, Honselmann KC, Hummel R, Dronov O, Kirichenko AV, Klinkhammer-Schalke M, Kleihues-van Tol K, Zeissig SR, Rades D, Keck T, Fernandez-Del Castillo C, Wellner UF, Wegner RE. Concepts and Outcomes of Perioperative Therapy in Stage IA-III Pancreatic Cancer-A Cross-Validation of the National Cancer Database (NCDB) and the German Cancer Registry Group of the Society of German Tumor Centers (GCRG/ADT). Cancers (Basel) 2022;14:868. [PMID: 35205616 DOI: 10.3390/cancers14040868] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Vitaloni M, Michl P, Löhr M, Stunt A, Rzadkowska P, Backman E, Sharara L, Neves V, Gruenberger T, Maravic Z. Pancreatic Cancer From the Patient Perspective: The Time to Act is Now. Journal of Patient Experience 2022;9:237437352211126. [DOI: 10.1177/23743735221112633] [Reference Citation Analysis]